

JLW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

LALVANI et al.

Appln. No. 09/308,725

Filed: May 24, 1999



Confirmation No. 6572

Atty. Ref.: 3772-19

T.C. / Art Unit: 1648

Examiner: S.B. Chen

FOR: ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS

\* \* \* \* \*

**INFORMATION DISCLOSURE STATEMENT**

May 18, 2006

U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statement (IDS) filed August 30, 2005, attached is Form PTO-1449 listing the enclosed documents which have been submitted by an opponent in an appeal involving related European Patent 0941478.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under 37 CFR § 1.97(f), to enable Applicants to comply fully. In particular, if any of the listed documents are missing or incomplete, please contact the undersigned who will provide another copy.

As provided by 37 CFR §§ 1.97(g) and (h), no inference should be made that this information and the listed references are prior art merely because they have been submitted for consideration. Furthermore, no representation is being made that a search


has been conducted or that this statement encompasses all possible material information.

Consideration of the foregoing and enclosures, as well as the return of a copy of the Form PTO-1449 with the Examiner's initials per M.P.E.P. § 609, are earnestly solicited. The Examiner is invited to contact the undersigned if any further information is needed.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Gary R. Tanigawa  
Reg. No. 43,180

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

(Use several sheets if necessary)

APPLN. NO.

09/308,725

APPLICANT

LALVANI et al.

FILING DATE

May 24, 1999

ATTY. DKT. NO.

3772-19

GROUP

Not Known

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AR						
BR						
CR						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					
	JR					
	KR					
	LR					
	MR					
	NR					
	OR					
	PR					

**OTHER DOCUMENTS (including Author, Title, Pertinent pages, Date, etc.)**

QR	Carrara et al. "Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy" Clin. Infect. Dis. 38:754-756 (2004)
RR	Cooper "The eukaryotic cell cycle " in Chapter 14 of <i>The Cell: A Molecular Approach, 2<sup>nd</sup> Ed.</i> , Sinauer Associates, 6 pages (2000)
SR	Lalvani et al. "Authors' reply" Lancet 361:2082-2083 (2003)
TR	Lalvani et al. "Enhanced contact tracing and spatial tracking of <i>Mycobacterium tuberculosis</i> infection by enumeration of antigen-specific T cells" Lancet 357:2017-2021 (2001)
UR	Lalvani et al. "Counting antigen-specific T cells: A new approach for monitoring response to tuberculosis treatment?" Clin. Infect. Dis. 38:757-759 (2004)
VR	Vincenti et al. "Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis" Mol. Med. 9:105-111 (2003)
WR	Wilkinson et al. "38000 MW antigen-specific major histocompatibility complex class I restricted interferon- $\gamma$ -secreting CD8 <sup>+</sup> T cells in healthy contacts of tuberculosis" Immunol. 95:585-590 (1998)
ZR	
AAR	
BBR	
CCR	
DDR	
EER	

*Examiner	Date Considered
-----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)